BIOPHTA funding news – Biotech Startup BIOPHTA Secures €6.5 Million in Seed Funding

This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.

Read also - Packwise funding news – IoT Startup Packwise Raises an Undisclosed Seven-Figure Amount of Funding

With a first program in the treatment of Glaucoma (Phase 1 in 2025, $8.7 billion market) and a second program in Macular Edema (Phase 1 in 2026, $9.6 billion market), BIOPHTA is currently targeting the two leading causes of blindness.

BIOPHTA overcomes adherence issues encountered with traditional eye drops as well as the high cost and invasiveness of frequent and painful intraocular injections. With this unique topical, non-invasive and self-administered therapy that provides continuous drug microdosing for 7 days, BIOPHTA improves the efficacy of eye treatments.

Jean Garrec, founder and CEO of BIOPHTA said, “With this funding, we are taking a major step towards the clinical validation of our technology in Glaucoma and then in Macular Edema. Our ambition does not stop here, and we remain fully dedicated on bringing sight-saving therapies to all patients in need of simple and efficient treatments, Our Seed investors syndicate brings not only the financial resources, but also complementary expertise and networks that will help structure the company. They will play a critical role in our development.”

Elaia and GO Capital, commented said, "The consortium of VC’s with UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), The technology developed by BIOPHTA is truly a game changer for the millions of patients worldwide who struggle with inadequate treatments for their eye diseases. Our VC syndicate is excited to support BIOPHTA’s growth.”

François Fournier, CEO of HTL Biotechnology and Eric Goupil, CEO of Unither Pharmaceuticals said, “We are delighted to support BIOPHTA and bring our respective expertise to this disruptive innovation in ophthalmology, which will improve patients’ lives,”

About BIOPHTA

BIOPHTA, which was founded in 2020 by two entrepreneurs with experience in developing ocular therapeutics, seeks to utilise the first 7-day continuous microdosing pharmaceutical form to significantly increase the effectiveness of eye treatments. Their dry mini-tablets are self-administered by patients; they rapidly gel and stick firmly to the surface of the eyes.